Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in the number of shares and votes in BioInvent International AB

Lund, Sweden, February 26, 2021 – BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company’s total number of shares as per February 26, 2021 amounts to 42,210,495 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 143 to Swedish and international institutional investors by issuance of 2,834,399 shares, announced on February 23, 2021.   About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical stage company that discovers and develops novel

Bluestep Bank AB (publ) Year-End Report 2020

The year in brief   Performance and financial position · Lending to the public amounted to SEK 16 116m (SEK 16 150m). Growth was reduced by both the sale of the personal loan portfolio and weakening of the Norwegian krone (NOK). Adjusted for personal loans and currency effects, lending rose by 12%. · New lending for the year increased by 7% to SEK 6 197m (SEK 5 805m). Adjusted for personal loans and currency effects, the increase was 22%. · Full year operating profit amounted to SEK 215m (SEK 275m). The decrease is attributable to one-off costs resulting from restructuring

Electrolux Professional acts for food support and sustainable cooking together with the Electrolux Food Foundation

Electrolux Professional is proud to announce the support of the Electrolux Food Foundation, an independent, non-profit organization that supports initiatives to inspire more sustainable food choices among professionals and consumers, and to support people in need in the communities around us.Since food is a major battleground in the fight against climate change, the foundation’s focus is well aligned with the Electrolux Professional commitment to contribute to change through its Sustainability Commitment, that supports the UN Agenda 2030 and Sustainable Development Goals. Niklas

Year-end report: First commercial installation of TES.POD started in Dubai

Azelio won its first order for TES.POD® in December. The company thus reached a major milestone in the commercialisation of its energy storage system. The order is from ALEC Energy, which will install Azelio’s technology in one of the world’s largest solar parks, the Mohammed Bin Rashid Al Maktoum Solar Complex in Dubai, where it will be part of a mini-grid together with inter alia solar panels and batteries. This will provide renewable energy 24 hours a day, which is an important step in meeting the climate transition. Azelio began installation on site on 20 December. In the fourth

Change in the number of votes in AcadeMedia

The votes in AcadeMedia has changed through conversion of 42,337 C shares to 42,337 ordinary shares. These shares now have one vote per share, totally 42,337 votes.  The conversion follows that all criteria in AcadeMedia’s share-based incentive program, adopted by the Annual General Meeting on November 24, 2017, was met and the qualifying participants have received these ordinary shares. As a result of the conversion, the number of votes has increased with 38,103.3 from 105,324,927.2 to 105,363,030.5. The total number of shares is unchanged. Today, the last trading day of the month,

K-Fast Holding AB: Interim report January–December 2020

Financial ratios for the period 1 January–31 December 2020 +---------------------------------+---------+--------+---------+---------+|  Financial ratios |    2020 |   2019 |   2020 |   2019 || | Oct–Dec |Oct–Dec | Jan–Dec | Jan–Dec |+---------------------------------+---------+--------+---------+---------+|  Rental income, SEK million |  56.2 | 44.7 | 203.9 |  156.8 |+---------------------------------+---------+--------+---------+---------+|  Profit from property |  19.1 | 8.6 | 75.3 |  52.9 |

Tecnotree Corporation Financial Report for Q4 and Full Year 2020 (unaudited)

Tecnotree Corporation Financial Statement Release 26 February 2021 at 09:00 (CET +1)Strong earnings and cash flow Fourth quarter 2020 · Fourth quarter net sales was EUR 14.2 (14.1) million. · The adjusted operating result for the quarter was EUR 4.3 (4.1) million and the operating result 4.3 (4.1) million. · The adjusted result for the quarter was EUR 4.3 (2.8) million and the result EUR 4.3 (2.8) million · The order book at the end of the period stood at EUR 32.1 (25.5) million. · Fourth quarter cash flow after investments was EUR 2.3 (-1.3) million. · Earnings per

Year-end report 2020

Gothenburg, February 26, 2021 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2020.Important events during the fourth quarter · In October, Vicore announced completion of patient enrollment in the phase II study in patients with COVID-19. · In October, Vicore announced the nomination committee for the 2021 Annual General Meeting. · In November, Vicore strengthened its pipeline with the acquisition of novel AT2R (angiotensin II type 2-receptor) agonists and decided on an issue in kind of 142,054 shares. · In November, Vicore announced changes in the

Saga Pure ASA: Prospectus Summary for transfer of listing from Euronext Expand to Oslo Børs

Oslo, Norway, 26 February 2021. Reference is made to the announcement on 24 February 2021 regarding Oslo Børs' resolution to admit the shares of Saga Pura ASA to listing on Oslo Børs. The first day of trading of the Company's shares on Oslo Børs will be on 1 March 2021. Consequently, the last day of trading of the Company's shares on Euronext Expand will be today, 26 February 2021. The ticker and ISIN of the Company's shares will remain unchanged. In connection with the transfer of listing from Euronext Expand to Oslo Børs, Saga Pure ASA hereby publish a prospectus summary, serving

Scout Gaming publishes Q4 2020: Revenues increased 69% to SEKm 16.9, EBITDA improved to SEKm -5.8, positive cashflow from operating activities

“We continue to undergo strong growth, revenues increased by 69% to SEK 16.9 million during the fourth quarter and during the full year 2020, total revenue base amounted to SEK 46.9 million. During the full year, total revenue base thus grew by 84 percent, despite a strong negative impact from COVID-19 at the end of the first and sizable parts of the second quarter - when the global sports calendar was halted. In a longer perspective, COVID-19 has resulted in a faster pace of digitalization in general and for companies operating in the entertainment sector in particular, which has benefited

Frill Holding AB publishes financial report 2020

STOCKHOLM, February 26, 2021 08:00 CET This information is information that Frill Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation.In December 2020, Frill Holding completed the acquisition of Bezzt AB and initiated a strategy that will strengthen the company and the brands associated with it. The acquisition is reported in accordance with the principles for reverse acquisition, where Bezzt is seen as the accounting acquirer and Frill Holding as the acquired party. Following the acquisition, the shareholders in Bezzt AB own 53% of the shares in Frill Holding

Swedbank Robur Sustainable Investments 2020

Swedbank Robur's annual report Sustainable Investments presents how the fund company integrate, support and push sustainability issues through their investments. At the beginning of 2020, Swedbank Robur started the implementation of their climate strategy, and launched six funds defined to be managed in line with the Paris Agreement. Swedbank Robur Råvarufond was also transformed into Transition Energy - and got a new and changed investment focus to encompass companies that contribute to the energy supply of the future. In addition, the fund company’s Policy for Responsible Investments was

ZINZINO AB (PUBL): YEAR-END REPORT 2020

INCREASED SHARE DIVIDEND AFTER RECORD CLOSING OF THE YEAR The fourth quarter of 2020 was the strongest quarter ever in the Company’s history regarding sales. Total revenues in the Group increased by 44% and amounted to SEK 340.4 (236.3) million. This is due to sales growth in all regions. The strongest growth continued to be found in the Central European countries, but Asia and North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 37.4 (6.3) million for the quarter. The EBITDA margin amounted to the record

Mycronic receives order for two SLX systems

Mycronic AB (publ) has received an order for two SLX mask writers from an existing customer in the USA. The total order value is between USD 8 and 12 million. Delivery of the first SLX system is scheduled for the fourth quarter of 2021, while delivery of the second system is scheduled for the first half-year of 2022.The SLX laser mask writer was launched in October 2019 to meet rising demand for photomasks for the semiconductor industry, which is driven by long-term trends, and to meet the future need for replacement and modernization. Photomasks made by laser mask writers are very

DanCann Pharma A/S publishes Year-end report for 2020

COPENHAGEN, Denmark, 26 February 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) today releases its results for the period 1 January – 31 December 2020. The Year-end report is available as an attached document to this press release and on www.dancann.com.Fourth quarter 2021 (1 October – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT) was -2,721 (-493) · Result per share (DKK) was -0.07 (-460,000)* · Equity ratio was 0.89 (-0.42) Full year 2020 (1 January – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT)

Recurring revenue continues to grow while churn remains at 0%

Interim Report October 1st – December 31th, 2020   • Despite a quarter with lead times affected by the pandemic, the Annual Recurring Revenue(ARR) increased with +37% year-on-year, to 23,8 MSEK.• The transformation in 2020 came to full completion in the fourth quarter. On a full-year basisrecurring revenues accounted for 90% of total revenues.• Churn in Q4 remains at 0%.• On January 25th, Safeture carried out a directed share issue of 4,6 million shares worth 38,6MSEK in new cash.Summary of Interim Report The Group Full Year (2020-01-01 to 2020-12-31) · Net

Year-end Report January-December 2020

SECURED FINANCING OF KARLATORNETOctober–December 2020 · Order bookings amounted to SEK 4,852 million (2,969). · Income amounted to SEK 2,166 million (2,253). · Operating loss amounted to SEK 47 million (97). · Cash flow from operating activities amounted to SEK 204 million (83). · Loss for the period amounted to SEK 72 million (63). · On December 17, 2020, Serneke and Balder entered a share transfer agreement meaning that Balder acquires 50 percent of the shares of Karlatornet AB (“the Joint Venture”). The Joint Venture is a newly established company that has acquired

Number of shares and votes in Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously announced rights issue and over-allotment option and which in total resulted in an increase of 27,847,833 class B shares. Today, the last trading day of the month, there are in total 52,135,651 shares in Medivir, of which all are class B shares with in total 52,135,651 corresponding voting rights. For additional information, please contactYilmaz Mahshid, CEOTelephone: +46 8 5468 3100E-mail: yilmaz.

myFC Holding AB (publ) year-end report January – December 2020

Full year January – December 2020· Net sales amounted to KSEK 0 (0) · Operating loss amounted to SEK -48 million (-165) · Earnings per share amounted to SEK -0.31 (-1.76) Quarter October – December 2020 · Net sales amounted to KSEK 0 (0) · Operating loss amounted to SEK -12 million (-17). · Earnings per share amounted to SEK -0.08 (-0.15) Significant events October – December · Directed share issues in myFC bring in SEK 36 million and a Share Subscription Agreement signed with Global Emerging Markets adds an additional SEK 150 million of available funding ·

Interim report October - December 2020

Quant releases the interim report for October - December 2020.October-December · Net sales for the period decreased by 13.7% to EUR 43.4 (50.3) million. Organically, net sales decreased by 7.3% · During the quarter, the contract portfolio decreased as nine contracts were lost, two contracts were won, and one contract was renewed. Portfolio run rate annualized net sales at the end of the quarter was EUR 140.5 million, compared to EUR 165.4 million during the third quarter of 2020 · Operating loss amounted to EUR -1.3 million, compared to a profit of EUR 0.8 million prior year ·

Nordic Iron Ore AB secures financing of SEK 20.9 million

Nordic Iron Ore AB ("Nordic Iron Ore" or "the Company") has decided to raise loans totaling SEK 20.9 million. The motive is to provide working capital to evaluate alternative financing options and continued design work.As previously announced, Nordic Iron Ore received a very positive result in November 2020 from the optimization study for the project in Blötberget. Based on this study, discussions have been initiated regarding the project's long-term financing. - The iron ore market is very strong, not least in terms of demand for the high-quality product that we will produce. These are

XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi

XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet.The investigator-initiated Phase II study is made possible by the three parties’ contributions to the trial. XNK will provide its novel autologous NK cell-based product to the study set to take place at the Karolinska University

There are no items matching the current filter
There are no more items matching the current filter
Back to top